The Markey Cancer Center (MCC) will utilize developmental funds, leveraged with institutional and philanthropic funds, to support pilot grants and strategic new faculty recruitments. Pilot grant funding ($125,000) from the CCSG will support collaborative and interdisciplinary cancer research focusing on MCC priority areas;funded projects will be carried out by interactions between MCC members in our four research programs and supported by our six shared resource facilities. Pilot funds will stimulate high return on investment research that makes a significant impact in the field of basic, clinical, population, or translational cancer research. New faculty recruitment priorities have been established based on the MCC Strategic Plan in consultation with Senior and Program Leaders and include recruitment of: 1) a senior level molecular epidemiologist in years 1-3 ($50,000 each year);and 2) a drug discovery scientist in years 4-5 ($50,000 each year).
Developmental funds will allow the MCC to invest in those areas of cancer research that present the greatest opportunity, and are vital to the continued success of the MCC. The MCC requests Developmental Funds from the CCSG to fund pilot research projects and to recruit new faculty;both endeavors will support the goal of translational research.
|Al-Darraji, Ahmed; Haydar, Dalia; Chelvarajan, Lakshman et al. (2018) Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease. PLoS One 13:e0200474|
|Jarrett, Stuart G; Carter, Katharine M; Bautista, Robert-Marlo et al. (2018) Sirtuin 1-mediated deacetylation of XPA DNA repair protein enhances its interaction with ATR protein and promotes cAMP-induced DNA repair of UV damage. J Biol Chem 293:19025-19037|
|Zaytseva, Yekaterina Y; Rychahou, Piotr G; Le, Anh-Thu et al. (2018) Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget 9:24787-24800|
|Choi, Yohan; Rosewell, Katherine L; Brännström, Mats et al. (2018) FOS, a Critical Downstream Mediator of PGR and EGF Signaling Necessary for Ovulatory Prostaglandins in the Human Ovary. J Clin Endocrinol Metab 103:4241-4252|
|Jiang, Kai; Liu, Yajuan; Zhang, Jie et al. (2018) An intracellular activation of Smoothened that is independent of Hedgehog stimulation in Drosophila. J Cell Sci 131:|
|Dhar, Sanjit K; Bakthavatchalu, Vasudevan; Dhar, Bithika et al. (2018) DNA polymerase gamma (Pol?) deficiency triggers a selective mTORC2 prosurvival autophagy response via mitochondria-mediated ROS signaling. Oncogene 37:6225-6242|
|Engle, Jeff A; Traynor, Anne M; Campbell, Toby C et al. (2018) Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J Oncol Pharm Pract 24:348-353|
|Kim, Ji Tae; Napier, Dana L; Weiss, Heidi L et al. (2018) Neurotensin Receptor 3/Sortilin Contributes to Tumorigenesis of Neuroendocrine Tumors Through Augmentation of Cell Adhesion and Migration. Neoplasia 20:175-181|
|Gedaly, Roberto; De Stefano, Felice; Turcios, Lilia et al. (2018) mTOR Inhibitor Everolimus in Regulatory T cell Expansion for Clinical Application in Transplantation. Transplantation :|
|Pi, Fengmei; Binzel, Daniel W; Lee, Tae Jin et al. (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82-89|
Showing the most recent 10 out of 359 publications